840 Memorial Drive
Cambridge, MA 02139
United States
617 498 0020
https://www.mersana.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 123
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Martin H. Huber M.D. | President, CEO & Director | 780,46k | N/D | 1961 |
Mr. Brian C. DeSchuytner | Senior VP, CFO & COO | 567,04k | N/D | 1978 |
Dr. Timothy B. Lowinger Ph.D. | Senior VP and Chief Science & Technology Officer | 587,53k | N/D | 1964 |
Ms. Alejandra Veronica Carvajal J.D. | Senior VP, Secretary & Chief Legal Officer | 558,12k | N/D | 1974 |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
L'ISS Governance QualityScore di Mersana Therapeutics, Inc. al 29 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 9.